Clinical trial design in the era of precision medicine
- PMID: 36045401
- PMCID: PMC9428375
- DOI: 10.1186/s13073-022-01102-1
Clinical trial design in the era of precision medicine
Abstract
Recent rapid biotechnological breakthroughs have led to the identification of complex and unique molecular features that drive malignancies. Precision medicine has exploited next-generation sequencing and matched targeted therapy/immunotherapy deployment to successfully transform the outlook for several fatal cancers. Tumor and liquid biopsy genomic profiling and transcriptomic, immunomic, and proteomic interrogation can now all be leveraged to optimize therapy. Multiple new trial designs, including basket and umbrella trials, master platform trials, and N-of-1 patient-centric studies, are beginning to supplant standard phase I, II, and III protocols, allowing for accelerated drug evaluation and approval and molecular-based individualized treatment. Furthermore, real-world data, as well as exploitation of digital apps and structured observational registries, and the utilization of machine learning and/or artificial intelligence, may further accelerate knowledge acquisition. Overall, clinical trials have evolved, shifting from tumor type-centered to gene-directed and histology-agnostic trials, with innovative adaptive designs and personalized combination treatment strategies tailored to individual biomarker profiles. Some, but not all, novel trials now demonstrate that matched therapy correlates with superior outcomes compared to non-matched therapy across tumor types and in specific cancers. To further improve the precision medicine paradigm, the strategy of matching drugs to patients based on molecular features should be implemented earlier in the disease course, and cancers should have comprehensive multi-omic (genomics, transcriptomics, proteomics, immunomic) tumor profiling. To overcome cancer complexity, moving from drug-centric to patient-centric individualized combination therapy is critical. This review focuses on the design, advantages, limitations, and challenges of a spectrum of clinical trial designs in the era of precision oncology.
Keywords: Clinical trials; Personalized medicine; Precision oncology; Real-world data.
© 2022. The Author(s).
Conflict of interest statement
Dr. Elena Fountzilas has the following financial relationships to disclose: Travel grants: Merck, Pfizer, and K.A.M Oncology/Hematology; Speaker fees: Roche, Leo, Pfizer; Stock ownership: Deciphera Pharmaceuticals, Inc.
Dr. Apostolia-Maria Tsimberidou has the following financial relationships to disclose: Research Funding (Institution): OBI Pharma, Parker Institute for Cancer Immunotherapy, Immatics, Tvardi Therapeutics, Tempus, Boston Biomedical, Placon Therapeutics, Karus Therapeutics, Agenus and Novocure. Consulting or Advisory Role: Vincerx, Diaccurate.
Dr. Razelle Kurzrock has the following financial relationships to disclose: Research Funding (Institution): Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols, Biologic Dynamics, Boehringer Ingelheim, Medimmune, and Guardant. Consulting role: X-Biotech, Loxo, Biologic Dynamics, Turning Point, TD2, Bicara, and Actuate Therapeutics. Speaker fees: Roche. Ownership interest: IDbyDNA and CureMatch, Inc. Board member: CureMatch and CureMetrix.
Dr. Henry Hiep Vo reports no relevant conflicts of interest.
Similar articles
-
Novel clinical trial designs emerging from the molecular reclassification of cancer.CA Cancer J Clin. 2025 May-Jun;75(3):243-267. doi: 10.3322/caac.21880. Epub 2025 Jan 22. CA Cancer J Clin. 2025. PMID: 39841128 Free PMC article. Review.
-
Review of precision cancer medicine: Evolution of the treatment paradigm.Cancer Treat Rev. 2020 Jun;86:102019. doi: 10.1016/j.ctrv.2020.102019. Epub 2020 Mar 31. Cancer Treat Rev. 2020. PMID: 32251926 Free PMC article. Review.
-
Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.Cancer J. 2019 Jul/Aug;25(4):282-286. doi: 10.1097/PPO.0000000000000393. Cancer J. 2019. PMID: 31335392 Free PMC article. Review.
-
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.Oncotarget. 2025 Mar 12;16:140-162. doi: 10.18632/oncotarget.28703. Oncotarget. 2025. PMID: 40073368 Free PMC article.
-
New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.Cancer Treat Rev. 2019 Feb;73:20-30. doi: 10.1016/j.ctrv.2018.12.003. Epub 2018 Dec 11. Cancer Treat Rev. 2019. PMID: 30572165 Review.
Cited by
-
Highly Multiplexed Tissue Imaging in Precision Oncology and Translational Cancer Research.Cancer Discov. 2024 Nov 1;14(11):2071-2088. doi: 10.1158/2159-8290.CD-23-1165. Cancer Discov. 2024. PMID: 39485249 Free PMC article. Review.
-
Transformative Potential of AI in Healthcare: Definitions, Applications, and Navigating the Ethical Landscape and Public Perspectives.Healthcare (Basel). 2024 Jan 5;12(2):125. doi: 10.3390/healthcare12020125. Healthcare (Basel). 2024. PMID: 38255014 Free PMC article. Review.
-
Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges.JCO Glob Oncol. 2024 Jan;10:e2300349. doi: 10.1200/GO.23.00349. JCO Glob Oncol. 2024. PMID: 38207249 Free PMC article.
-
Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade.Pharmaceuticals (Basel). 2023 Feb 7;16(2):253. doi: 10.3390/ph16020253. Pharmaceuticals (Basel). 2023. PMID: 37259400 Free PMC article. Review.
-
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear.Ther Adv Med Oncol. 2024 Apr 4;16:17588359241234487. doi: 10.1177/17588359241234487. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38584763 Free PMC article. Review.
References
-
- Warner JL, Sethi TK, Rivera DR, Venepalli NK, Osterman TJ, Khaki AR, et al. Trends in FDA cancer registration trial design over time, 1969-2020. J Clin Oncol. 2020;38(15_suppl):2060. doi: 10.1200/JCO.2020.38.15_suppl.2060. - DOI
-
- Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi: 10.1016/S1470-2045(20)30445-9. - DOI - PubMed
-
- Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;38(1):1–10. doi: 10.1200/JCO.19.02105. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical